VOLABIOS Validation and Comparitive Multi-Omics Benchmarking of Fluid-Derived Volatilomics Biomarkers for the Prevention and Early detection of Schizophrenia
- Coordinator
- Technion - Israel Institute of Technology, Israel
- Runs
- 1 January 2025 to 30 June 2029
- Status
- Running
- EU funding
- €8.0m
- Total cost
- —
- Partners
- 22 organisations in 11 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101156162
What the project is doing
In the project's own words, from its summary on CORDIS.
Schizophrenia (SZ) impacts around 1% of the global population, posing diagnostic challenges that lead to a misdiagnosis rate of 23-40%. The need for reliable biomarkers is crucial to improve early detection and treatment outcomes. VOLABIOS aims to revolutionize SZ management by harnessing innovative real-time and portable spectrograph technology to validate volatile organic compounds (VOCs) as non-invasive and cost-effective biomarkers detectable during the early stages of the disease.
This entails extensive data analysis, prospective clinical studies involving 3,692 subjects across six centres, and a blind validation study with 1,000 subjects, focusing on longitudinal monitoring of at-risk individuals to identify early SZ transition. To further substantiate the efficacy of VOCs and gain profound insights, VOLABIOS will integrate VOC analysis with genomics, proteomics, and transcriptomics. This integration will be supported by a biobank comprising approximately 4,000 samples and a dataset consisting of 9 million records.
By considering external and personal risk factors as well as biological responses, VOLABIOS aims to unravel intricate correlations that contribute to SZ development. This comprehensive approach will enhance prediction accuracy, facilitate early detection, and improve management strategies. Furthermore, VOLABIOS plans to explore the real-time effects of validated VOCs through controlled in-vivo experiments using animal models, providing valuable information about associated cellular and molecular pathways.
VOLABIOS's endeavours to validate and establish EU-wide SZ diagnosis protocols are set to significantly enhance patient care and healthcare efficiency, marking a substantial step forward in addressing the complexities surrounding SZ.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Technion - Israel Institute of Technology | Haifa | Israel | Coordinator |
| Zentrum Fur Soziale Innovation GmbH | Wien | Austria | Participant |
| Ainigma Technologies | Leuven | Belgium | Participant |
| Timelex | Bruxelles / Brussel | Belgium | Participant |
| Betthera Sro | Hradec Kralove | Czechia | Participant |
| Gesellschaft Zur Forderung Empirisch Begrundeter Therapieansatze | Aachen | Germany | Participant |
| Heinrich-Heine-Universitaet Duesseldorf | Dusseldorf | Germany | Participant |
| Universitaetsklinikum Aachen | Aachen | Germany | Participant |
| Cubic Snail O.e. | Thessaloniki | Greece | Participant |
| Ethniko Kentro Erevnas Kai Technologikis Anaptyxis | Thermi Thessaloniki | Greece | Participant |
| Exus Software Monoprosopi Etairia Periorismenis Evthinis | Athina | Greece | Participant |
| Ypourgeio Ygeias | Athina | Greece | Participant |
| Fundacion Para La Gestion De La Investigacion En Salud De Sevilla | Sevilla | Spain | Third party |
| Servicio Andaluz De Salud | Sevilla | Spain | Participant |
| Universidad De La Rioja | Logrono | Spain | Participant |
| Firalis | Huningue | France | Participant |
| Firalis Molecular Precision SA | Huningue | France | Third party |
| Smart Nano Sense Ltd | Haifa | Israel | Participant |
| Technion Research and Development Foundation Ltd | Haifa | Israel | Third party |
| Lietuvos Sveikatos Mokslu Universitetas | Kaunas | Lithuania | Participant |
| Universidade De Coimbra | Coimbra | Portugal | Participant |
| The Chancellor Masters and Scholars of the University of Cambridge | Cambridge | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI